Active Biotech : Annual Report 2012 Active Biotech AB (publ)

         Active Biotech : Annual Report 2012 Active Biotech AB (publ)

Active Biotech's Annual Report 2012 (in Swedish) is now available for download
at The English version will be available within short.

The Annual Report will only be digitally distributed.

Lund, April 15, 2013

Active Biotech AB (publ)

Tomas Leanderson
President & CEO

For further information, please contact:
Hans Kolam
Tel +46 (0)46 19 20 44

Active Biotech AB (NASDAQ  OMX NORDIC: ACTI) is  a biotechnology company  with 
focus on  autoimmune/inflammatory diseases  and  cancer. Projects  in  pivotal 
phase are  laquinimod,  an  orally administered  small  molecule  with  unique 
immunomodulatory  properties  for   the  treatment   of  multiple   sclerosis, 
tasquinimod for  prostate cancer  and ANYARA  primarily for  the treatment  of 
renal cell cancer.  In addition,  laquinimod is  in Phase  II development  for 
Crohn's and Lupus.  The company also  has one additional  project in  clinical 
development, the orally  administered compound 57-57  for Systemic  Sclerosis. 
Please visit for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted
for publication at 10:00 a.m. CET on April 15, 2013.

Annual Report 2012 Active Biotech AB (publ)


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Active Biotech via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.